A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies

Nat Commun. 2019 Jan 21;10(1):366. doi: 10.1038/s41467-018-08166-x.

Abstract

Comprehensive preclinical studies of Myelodysplastic Syndromes (MDS) have been elusive due to limited ability of MDS stem cells to engraft current immunodeficient murine hosts. Here we report a MDS patient-derived xenotransplantation model in cytokine-humanized immunodeficient "MISTRG" mice that provides efficient and faithful disease representation across all MDS subtypes. MISTRG MDS patient-derived xenografts (PDX) reproduce patients' dysplastic morphology with multi-lineage representation, including erythro- and megakaryopoiesis. MISTRG MDS-PDX replicate the original sample's genetic complexity and can be propagated via serial transplantation. MISTRG MDS-PDX demonstrate the cytotoxic and differentiation potential of targeted therapeutics providing superior readouts of drug mechanism of action and therapeutic efficacy. Physiologic humanization of the hematopoietic stem cell niche proves critical to MDS stem cell propagation and function in vivo. The MISTRG MDS-PDX model opens novel avenues of research and long-awaited opportunities in MDS research.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antigens, CD / genetics
  • Antigens, CD / immunology
  • Biomarkers / metabolism
  • Cytokines / genetics
  • Cytokines / immunology
  • Disease Models, Animal*
  • Gene Expression
  • Gene Knock-In Techniques
  • Graft Survival*
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hematopoietic Stem Cells / immunology*
  • Hematopoietic Stem Cells / pathology
  • Humans
  • Mice
  • Mice, Transgenic
  • Myelodysplastic Syndromes / immunology*
  • Myelodysplastic Syndromes / pathology
  • Stem Cell Niche / immunology*
  • Transplantation, Heterologous

Substances

  • Antigens, CD
  • Biomarkers
  • Cytokines